{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:18Z","timestamp":1753892058768,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive subtype of peripheral T-cell lymphoma. The current prognosis with the first-line standard of care remains unsatisfactory, necessitating the exploration of more effective treatment options. We reported 5 cases of AITL receiving CMOP (mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine, and prednisone). Cases 1 and 2 initially received CHOP as first-line induction therapy but switched to CMOP due to inadequate efficacy and cardiac adverse events. Cases 3, 4, and 5 were newly diagnosed and received CMOP. All patients achieved complete remission with acceptable cardiotoxicities and hematologic toxicities. After study treatment discontinuation, Cases 1 and 3 underwent autologous stem cell transplantation, and Cases 4 and 5 received oral maintenance agents. At the last follow-up, 4 patients remained in remission and 1 (Case 2) exhibited tumor recurrence. CMOP showed promise as a potential treatment option for AITL patients. Further research is essential to identify its efficacy and safety.<\/jats:p>","DOI":"10.3389\/fonc.2024.1331154","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:31:21Z","timestamp":1706675481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Lijie","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood J Am Soc Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"De Leval","year":"2010","journal-title":"Br J haematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060456","article-title":"Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma","volume":"28","author":"Mohammed Saleh","year":"2021","journal-title":"Curr Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1758835920923829","DOI":"10.1177\/1758835920923829","article-title":"Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients","volume":"12","author":"Sun","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(83)90008-7","article-title":"Mitoxantrone (novantrone): a review of experimental and early clinical studies","volume":"10","author":"Smith","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c05194","article-title":"Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors","volume":"14","author":"Mei","year":"2020","journal-title":"ACS nano"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2523-8","article-title":"Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy","volume":"74","author":"Yang","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"B9","first-page":"10","article-title":"Overview of mitoxantrone-a potential candidate for treatment of breast cancer","volume":"14","author":"Preethi","year":"2022","journal-title":"Int J Appl Pharm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med Res Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141752","article-title":"Safety and efficacy of mitoxantrone hydrochloride liposome in patients with relapsed or refractory peripheral T-cell lymphoma and extranodal NK\/T-cell lymphoma: A prospective, single-arm, open-label, multi-center, phase II clinical trial","volume":"136","author":"Gao","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5248","article-title":"Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China","volume":"12","author":"Wei","year":"2023","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2042247","article-title":"The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis","volume":"15","author":"Zhai","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10637-021-01182-7","article-title":"Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial","volume":"40","author":"Wang","year":"2022","journal-title":"Investigational New Drugs"},{"key":"B21","article-title":"Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride","volume":"45","author":"Wang","year":"2010","journal-title":"Yao xue xue bao= Acta Pharm Sin"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1331154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:31:24Z","timestamp":1706675484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1331154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":21,"alternative-id":["10.3389\/fonc.2024.1331154"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1331154","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"article-number":"1331154"}}